drugset / Trial / NCT03943901
Split-Dose R-CHOP for Older Adults With DLBCL
Phase 2
Active not recruiting
27 enrolled
University of Wisconsin, Madison
Medical College of Wisconsin · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up; certain participants 70-74 may be eligible) that is often excluded from clinical trials. Participants can expect to be on study for 2.5 years (treatment for 6 months and 2 years of post treatment follow-up).
Timeline
- Start
- 2021-02-17
- Primary completion
- 2025-01-13
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 375 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Prednisone | Other / unclassified | 50 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Vincristine | Small molecule | 1 mg | Intravenous |
| Background | Pegfilgrastim | Protein / enzyme biologic | 6 mg | — |